| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
BASEL—Life science company Lonza Group announced it granted a non-exclusive worldwide license to Brussels-based biopharmaceutical firm UCB for its GS Gene Expression System. The current license covers the use of the platform for R&D purposes, but the agreement also carries an option to license the system for commercial purposes. Financial terms were not disclosed.
 
The platform is used in the production of therapeutic recombinant proteins and monoclonal antibodies, markets that have grown significantly in recent years as pharmaceutical and biotechnology companies strive to improve the safety profiles of their products.
 
According to a 2006 report by Kalorama Information, the global market for protein therapeutics in 2005 was $51 billion and it is expected to reach $87 billion by 2010. A similar 2005 report by Frost & Sullivan described the therapeutic monoclonal antibody market at $8.7 billion in 2005, surpassing $16 billion by 2012.
 
"Protein therapeutics are revolutionizing modern medicine and showing no signs of slowing up," notes Steven Heffner, Kalorama publisher. "With little threat from generics due to the specialized manufacturing of cell lines and strong process controls, strong product innovation, and the premium pricing afforded to them due to their high-tech ingredient profiles and the diseases they target, we are witnessing a pharmacological wonder where everyone—including consumers—is a winner."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue